Factory 99% Raltegravir Powder CAS 518048-05-0 Chemical Intermediate Anti-Aids Raltegravir

• Customization: Available
• Powder: Yes
• Customized: Customized
• Model NO.: A611
• Certification: GMP, HSE, ISO 9001, USP, BP
• Suitable for: Elderly, Children, Adult
• State: Powder
• Purity: >99%
• Name: Raltegravir
• CAS: 518048-05-0
• Appearance: White Powder
• Assay: 99%
• OEM: Available
• Sample: Available
• Suitable: Adult
• MOQ: 1g
• Function: Anti-Aids
• Transport Package: Foil Bag
• Specification: 99
• Trademark: /
• Origin: China
• Production Capacity: 10000 Kgs Per Month

Product Description

 

Product Name	Raltegravir
Appearance	White Powder
CAS NO.	518048-05-0
MF	C28H20F6N8O4
Storage	Keep in a cool, dry, dark location

 

Raltegravir is a potent antiviral agent specifically designed for the treatment of HIV-1 infection. It belongs to the class of integrase strand transfer inhibitors (INSTIs), which target the viral integrase enzyme, a crucial component in the HIV replication cycle.

 

1. HIV Therapy: Raltegravir is primarily used in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and pediatric patients.
2. Resistant Strains: It is particularly effective against HIV strains that have developed resistance to other antiretroviral drugs, such as nucleoside reverse transcriptase inhibitors (NRTIs) and non-nucleoside reverse transcriptase inhibitors (NNRTIs).
3. Treatment-Naive and Experienced Patients: Raltegravir can be prescribed to both treatment-naive patients initiating antiretroviral therapy and those who have already undergone multiple treatment regimens.

1. Inhibition of Integrase: By binding to the integrase enzyme, Raltegravir blocks the integration of HIV-1 DNA into the host cell's genome. This step is essential for the virus to replicate and spread.
2. Viral Load Reduction: By inhibiting the integrase function, Raltegravir significantly reduces the viral load in the body, helping to control the progression of HIV-1 infection.
3. Improved Immune Function: Over time, the reduction in viral load can lead to an improvement in the patient's immune system, reducing the risk of opportunistic infections and other HIV-related complications.